OM1

OM1

Real-world data analytics for patient outcomes

Overview

OM1 provides healthcare analytics and AI-driven insights using real-world data to improve patient outcomes. It collects data from sources like electronic health records, insurance claims, and patient registries to create real-world evidence that informs decisions for chronic diseases and treatments. Its flagship product, Aspen, automates evidence generation by applying AI to identify patients with specific conditions and predict treatment outcomes, helping pharma companies, healthcare providers, and IDNs make better decisions about care and therapy development. Compared with others, OM1 emphasizes scalable real-world data fusion, automated evidence generation, and strong collaborations with large healthcare organizations to validate long-term outcomes. The company aims to advance predictive medicine and support the development and optimization of treatments, ultimately improving patient care and outcomes.

About OM1

Simplify's Rating
Why OM1 is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$172.3M

Headquarters

Boston, Massachusetts

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • PhenOM launches Orion, Lyra, Polaris enhance pharma patient journey insights.
  • Alzheimer’s PremiOM dataset covers 17,000 patients, aiding early detection trials.
  • Europe expansion strengthens AI-RWE support for pharmaceutical organizations.

What critics are saying

  • Komodo Health's 600M patient platform captures OM1's pharma RWE contracts.
  • Flatiron Health's FDA-qualified datasets dominate OM1's chronic disease verticals.
  • FDA 2025 RWE framework blocks OM1's unvalidated data for label expansions.

What makes OM1 unique

  • OM1's PhenOM platform powers AI phenotyping from 340 million patients for personalized medicine.
  • OM1 specializes in chronic diseases like CRS, Asthma, and Alzheimer's with PremiOM datasets.
  • OM1 pioneered AI in RWD since 2017, holding 10+ patents for outcome prediction.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$172.3M

Above

Industry Average

Funded Over

5 Rounds

Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

5%

2 year growth

3%
Postmedia Network
May 8th, 2025
OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025

OM1 to present groundbreaking research on GLP-1 agonists and Suicidal Ideation at ISPOR 2025.

Silicon Canals
Mar 12th, 2025
OM1 Expands into Europe to Strengthen Support for Life Sciences with AI-Driven Real-World Evidence Solutions

BOSTON - (BUSINESS WIRE) - OM1, a leading provider of real-world data (RWD) and AI-driven insights for life sciences, today announced its expansion into Europe to better support pharmaceutical and healthcare organizations with high-quality, AI-enhanced real-world evidence (RWE) solutions.

IMARC Group
Dec 4th, 2024
Global Biobanking Market Expected to Reach USD 101.1 Billion by 2033 - IMARC Group

For instance, OM1 launched its new AI-based platform in April 2023 to provide personalized information regarding clinical trials, use, risk, treatment, and diagnosis.

Thailand Business Directory
Sep 18th, 2024
OM1 Earns Frost & Sullivan's 2024 North American New Product Innovation Award for Transforming Real-world Evidence Analytics Solutions Industry with Its Pioneering AI-powered Platforms

OM1 earns Frost & Sullivan's 2024 North American New Product Innovation Award for transforming real-world evidence analytics solutions industry with its pioneering ai-powered platforms.

Business Wire
Aug 21st, 2024
OM1 Appoints Catherine Richards as President

OM1 appoints Catherine Richards as President.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for OM1 right now.

Find jobs on Simplify and start your career today

We update OM1's jobs every few hours, so check again soon! Browse all jobs →